Treatment of Posterior Uveitis in Birdshot Chorioretinopathy

Birdshot chorioretinopathy (BCR) defines a distinct subset of posterior uveitis with a strong immunogenetic signature. More than 90% of patients with BCR carry the HLA-A29 haplotype, making it one of the most HLA-associated uveitic entities known. This immunological context directly shapes the treatment approach.

Clinical scenario

Posterior uveitis occurring in the setting of birdshot chorioretinopathy — a condition characterised by its near-universal association with the HLA-A29 antigen.

Treatment approach

BCR-associated posterior uveitis is managed with targeted biological agents that have shown a favorable response in this specific population. The complete regimen — including agent selection, sequencing, and full clinical guidance — is available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.4103/0301-4738.58470

More than 90% of the patients with BCR are HLA-A29 positive.

Biologicals such as infliximab for the treatment of refractory non-infective posterior uveitis and severe SFU and daclizumab and tacrolimus for the treatment of BCR have been used with favorable response.

View source ↗